Gomez German G, Kruse Carol A
Department of Pathology, University of Colorado Health Sciences Center, Denver, CO, USA.
J Immunother. 2007 Apr;30(3):261-73. doi: 10.1097/01.cji.0000211339.81211.25.
Two immunoresistant (IR) glioma cell variants, 13-06-IR29 and 13-06-IR30, were cloned from 13-06-MG glioma cell populations after receiving continuous immunoselective pressure from multiple alloreactive cytotoxic T lymphocyte (aCTL) preparations. Reapplication of aCTL immunoselective pressure to the IR clones, displaying a partial regain in sensitivity to aCTL after removal of the selective pressure, restored the resistance. The IR variants exhibited cross-resistance to non-human leukocyte antigen (HLA)-restricted effector cells and gamma-irradiation, but not to carmustine. The IR clones were characterized for factors that might contribute to the immunoresistance. The aCTL adhesion to extracellular matrix extracts derived from either the IR clones or the parental cells was similar and not impaired. Furthermore, aCTL binding to parental cells and IR clones was equal. Down-regulation of the cell recognition molecules, class I HLA or intercellular adhesion molecule-1 (ICAM-1), that would inhibit their recognition by aCTL was not observed on the IR clones. The down-regulation of Fas by the IR clones correlated with their resistance to FasL-induced apoptosis. HLA-G or FasL that might provide an immunotolerant environment or provide a means of counterattack to aCTL, respectively, were not associated with the IR phenotype. The aCTL, coincubated with the IR clones and parental cells, displayed up-regulation of multiple secreted cytokines. A significant up-regulation of bioactive transforming growth factor (TGF)-beta was observed in the IR clones compared with the parental cells. These data suggest that increased secretion of bioactive TGF-beta may inhibit aCTL lysis of the IR clones. Disruption of the TGF-beta signaling pathway may circumvent the resistance.
在受到多种同种异体反应性细胞毒性T淋巴细胞(aCTL)制剂的持续免疫选择压力后,从13-06-MG胶质瘤细胞群体中克隆出两种免疫抗性(IR)胶质瘤细胞变体,即13-06-IR29和13-06-IR30。对IR克隆重新施加aCTL免疫选择压力,在去除选择压力后,IR克隆对aCTL的敏感性部分恢复,之后又恢复了抗性。IR变体对非人类白细胞抗原(HLA)限制的效应细胞和γ射线照射表现出交叉抗性,但对卡莫司汀没有抗性。对IR克隆进行了可能导致免疫抗性的因素的表征。aCTL对源自IR克隆或亲本细胞的细胞外基质提取物的粘附是相似的,且未受损。此外,aCTL与亲本细胞和IR克隆的结合是相等的。在IR克隆上未观察到会抑制aCTL对其识别的细胞识别分子I类HLA或细胞间粘附分子-1(ICAM-1)的下调。IR克隆中Fas的下调与其对FasL诱导的凋亡的抗性相关。可能分别提供免疫耐受环境或提供反击aCTL手段的HLA-G或FasL与IR表型无关。与IR克隆和亲本细胞共孵育的aCTL显示出多种分泌细胞因子的上调。与亲本细胞相比,在IR克隆中观察到生物活性转化生长因子(TGF)-β的显著上调。这些数据表明,生物活性TGF-β分泌增加可能会抑制aCTL对IR克隆的裂解。破坏TGF-β信号通路可能会规避这种抗性。